% placebo, 95% CI of the difference: 2.8-7.7; p=0.0001;prurigo nodularis:13.4% nemolizumab-treated compared to 4.3% placebo; 95% CI - of the difference: 4.0-13.0; p=0.0013)1

By Day 14, a quarter of patients with atopic dermatitis and more than a third of patients with prurigo nodularis achieved significant and clinically meaningful responses in both itch and sleep outcomes1


Taken individually, each study (ARCADIA 1 and 2 for atopic dermatitis and OLYMPIA 1 and 2 for prurigo nodularis) also demonstrated a significant PP-NRS response at Day 2.1

These new data reinforce nemolizumab’s efficacy and its potential to deliver rapid relief from itch – the most burdensome symptom for many patients with atopic dermatitis and prurigo nodularis.13,14

Media can find more information and resources on atopic dermatitis and prurigo nodularis inthis toolkit.

About Nemluvio®(nemolizumab)
Nemolizumab was initially developed by C
=*=*=*=*=*=
当前为第5/16页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页